These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36575017)

  • 1. Factors and Reasons for Non-vaccination among Patients with Systemic Lupus Erythematosus: A Single-centre, Cross-sectional Study.
    Miyake H; Minoda Sada R; Manabe A; Tsugihashi Y; Hatta K
    Intern Med; 2023 Sep; 62(17):2483-2491. PubMed ID: 36575017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-centre, cross-sectional study on the factors and reasons for non-vaccination among patients with rheumatoid arthritis.
    Miyake H; Sada RM; Tsugihashi Y; Hatta K
    Mod Rheumatol; 2023 Dec; 34(1):79-86. PubMed ID: 36702156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan.
    Furer V; Weil C; Chodik G; Slav SA; Blonder SN; Fisher-Shoval Y; Barak M; Elkayam O
    J Rheumatol; 2024 May; 51(5):505-516. PubMed ID: 38302167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
    Rezende RPV; Oliveira-Santos M; Andrade LEC; Klumb EM
    Lupus; 2023 Apr; 32(5):694-703. PubMed ID: 36705619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus.
    Lawson EF; Trupin L; Yelin EH; Yazdany J
    Semin Arthritis Rheum; 2015 Jun; 44(6):666-71. PubMed ID: 25701500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
    Fernández-Prada M; Brandy-García AM; Rodríguez-Fonseca OD; Huerta-González I; Fernández-Noval F; Martínez-Ortega C
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):97-102. PubMed ID: 29752214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
    Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
    Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
    Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
    J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of systemic lupus erythematosus patients' attitudes toward influenza and pneumococcal vaccination in Southwest China.
    Chen Y; Chen B; Shen X; Zhou A; Liang Y; Wang Y; Chen H
    Front Public Health; 2022; 10():1018899. PubMed ID: 36605245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.